Trastuzumab is a monoclonal antibody designed to inhibit HER2 dimerization and is approved as a novel neoadjuvant therapy for HER2-positive breast cancer, as well as metastatic breast and gastric cancers. Here, ERBB2 is linked to breast carcinoma.